NNC0113 6856
Alternative Names: NNC0113-6856Latest Information Update: 11 Oct 2023
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 06 Oct 2023 Novo Nordisk plans phase I pharmacokinetics trial in Japanese healthy adult volunteers in Germany (PO) (NCT06069895)
- 04 Oct 2023 Novo Nordisk initiates phase I pharmacokinetics trial in Japanese healthy adult volunteers in Germany (PO) (NCT06069895)
- 27 Mar 2023 Novo Nordisk completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in Germany (PO, IV) (NCT05521256)